Amgen posted third-quarter earnings Monday that beat Wall Street estimates, as the company reported strong drug sales and benefited from cost-cutting once restructuring costs were excluded.

The Thousand Oaks biotech reported net income of $1...

Join our Membership to get the full story.


Are you a current Member? Sign In